Cargando…

Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

OBJECTIVE: Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test?...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villy, M.-C., Masliah-Planchon, J., Melaabi, S., Trabelsi Grati, O., Girard, E., Bataillon, G., Vincent-Salomon, A., Le Gall, J., Golmard, L., Stoppa-Lyonnet, D., Bieche, I., Colas, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435919/ https://www.ncbi.nlm.nih.gov/pubmed/34541275 http://dx.doi.org/10.1016/j.gore.2021.100855

Ejemplares similares

A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation
por: Trabelsi-Grati, Olfa, et al.
Publicado: (2020)

Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon
por: Jalkh, Nadine, et al.
Publicado: (2012)

Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer
por: Basse, Clémence, et al.
Publicado: (2023)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

The biological effects and clinical implications of BRCA mutations: where do we go from here?
por: Stoppa-Lyonnet, Dominique
Publicado: (2016)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
por: Debbabi, Inès, et al.
Publicado: (2023)

Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
por: Moreira, A., et al.
Publicado: (2021)

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Grandal, Beatriz, et al.
Publicado: (2020)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Low expression of bcl-2 in Brca1-associated breast cancers
por: Freneaux, P, et al.
Publicado: (2000)

Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons
por: Pages, S, et al.
Publicado: (2001)

Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2018)

First description of a sporadic breast cancer in a woman with BRCA1 germline mutation
por: Curtit, Elsa, et al.
Publicado: (2015)

Value of the loss of heterozygosity to BRCA1 variant classification
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2022)

Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images
por: Lazard, Tristan, et al.
Publicado: (2022)

Unusually Aggressive Actinic Keratosis of the Eyelid and Conjunctiva
por: AL-HAGE, Jana, et al.
Publicado: (2023)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022)

Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie
por: Basse, Clémence, et al.
Publicado: (2018)

High-grade childhood intra-parenchymal brain tumor clustering with ATRT and expanding the cancer spectrum related to inherited SMARCE1 truncating variations
por: Forest, Fabien, et al.
Publicado: (2022)

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)

Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?
por: Laot, Lucie, et al.
Publicado: (2022)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Cytidine deaminase activity increases in the blood of breast cancer patients
por: Buhagiar-Labarchède, Géraldine, et al.
Publicado: (2022)

Author Correction: Cytidine deaminase activity increases in the blood of breast cancer patients
por: Buhagiar‑Labarchède, Géraldine, et al.
Publicado: (2022)

Recurrent FAN1 p.W707X Pathogenic Variant Originating Before ad 1800 Underlies High Frequency of Karyomegalic Interstitial Nephritis in South Pacific Islands
por: Gueguen, Lorraine, et al.
Publicado: (2021)

Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer
por: Harpaz, Noa, et al.
Publicado: (2020)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing
por: Eeckhoutte, Alexandre, et al.
Publicado: (2020)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer
por: Brédart, A, et al.
Publicado: (2013)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis
por: Masliah-Planchon, Julien, et al.
Publicado: (2013)

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers
por: Jiao, Yue, et al.
Publicado: (2021)

Rapid progression of prostate cancer in men with a BRCA2 mutation
por: Narod, S A, et al.
Publicado: (2008)

Corrigendum to “Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer”
por: Harpaz, Noa, et al.
Publicado: (2020)

Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic
por: Saghatchian, Mahasti, et al.
Publicado: (2022)

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)
por: Lecarpentier, Julie, et al.
Publicado: (2012)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sh01tjvv52sd17a2v37e7l05da